Fig 1.
The prevalence and spectrum of SMAD4 mutations in the MD Anderson study patients and TCGA data.
(A) The prevalence and spectrum of SMAD4 mutations in the study patients who underwent full-length sequencing (n = 49). (B) The prevalence and spectrum of SMAD4 mutations in TCGA data (n = 220 patients).
Table 1.
Demographic and tumor characteristics of CRC patients according to SMAD4 mutation status.
Fig 2.
Comparison of survival curves in patients with metastatic CRC according to SMAD4 mutation status.
Median OS durations of 29 months (95% CI, 20–48 months) and 56 months (95% CI, 51–63 months) were observed in patients with mutated and wild-type SMAD4, respectively.
Table 2.
Univariate and multivariate Cox regression analyses of OS in metastatic CRC patients (n = 600).
Fig 3.
Progression-free survival curves for CRC patients who received anti-EGFR treatment according to SMAD4 mutation status.
All patients were wild-type for KRAS, NRAS, and BRAF genes.
Fig 4.
Comparison of the incidences of TGF-β pathway mutations across different molecular subtypes.
Fig 5.
Comparison of the incidences of SMAD4 mutations across different molecular subtypes.
Fig 6.
OncoPrint showing the distribution of TGF-β mutations across different molecular subtypes in TCGA CRC samples.
Fig 7.
OncoPrint of genomic alterations in TCGA CRC cases (n = 220) showing mutations of SMAD4, KRAS, NRAS, and BRAF.